AstraZeneca PLC (LON:AZN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of AstraZeneca PLC (LON:AZN) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is £152.17.

Several brokerages recently issued reports on AZN. Jefferies Financial Group reiterated a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a research report on Monday, August 3rd. Berenberg Bank reaffirmed a “buy” rating and issued a £160 price target on shares of AstraZeneca in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a £115 price target on shares of AstraZeneca in a research note on Wednesday. Finally, Citigroup increased their price objective on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th.

AstraZeneca Stock Up 1.3%

Shares of AstraZeneca stock opened at £122.40 on Friday. The company has a market capitalization of £189.83 billion, a P/E ratio of 18.32, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The business has a 50-day moving average of £128.57 and a two-hundred day moving average of £138.20. AstraZeneca has a 1 year low of £107.84 and a 1 year high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.